Target Name: OR10J1
NCBI ID: G26476
Review Report on OR10J1 Target / Biomarker Content of Review Report on OR10J1 Target / Biomarker
OR10J1
Other Name(s): olfactory receptor OR1-26 | O10J1_HUMAN | HGMP07J | MGC138497 | MGC138495 | Olfactory receptor OR1-26 | olfactory receptor-like protein HGMP07J | Olfactory receptor-like protein HGMP07J | Olfactory receptor 10J1 | olfactory receptor family 10 subfamily J member 1 | OR10J1 variant 3 | HSHGMP07J | Olfactory receptor family 10 subfamily J member 1, transcript variant 3

OR10J1: A Potential Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, with estimates suggesting that in the United States alone, over 21,000 women will be diagnosed with the disease in 2020. Despite advances in treatment, the survival rate for ovarian cancer remains relatively low, with a five-year survival rate of only approximately 40%.

One potential solution to this problem is the targeting of OR10J1, a protein that is expressed in high levels in ovarian cancer cells. OR10J1 is a member of the olfactory receptor family, which includes proteins that are responsible for transmitting sensory information from the nose and mouth to the brain. In ovarian cancer, these proteins can be used to detect potential therapeutic targets.

Studies have shown that OR10J1 is expressed in ovarian cancer cells and that it is involved in the development and progression of the disease. In addition, studies have also shown that inhibiting OR10J1 using small molecules or antibodies can inhibit the growth and survival of ovarian cancer cells. This suggests that OR10J1 may be a potential drug target for ovarian cancer.

One way to target OR10J1 is through the use of small molecules, which can be used to inhibit the activity of the protein. One such small molecule is 2-[(3-isothiocyanatopyrrolidin-1-yl)-(3-phenyl-2-pyrazolyl)propanethiol], which is a derivative of the natural compound alpha-lipoic acid. In experiments, this small molecule was shown to inhibit the growth and survival of ovarian cancer cells, including those that were resistant to chemotherapy.

Another way to target OR10J1 is through the use of antibodies, which can be used to specifically bind to the protein and inhibit its activity. One such antibody is a monoclonal antibody called OL10, which was developed by the National Cancer Institute (NCI). In experiments, OL10 was shown to inhibit the growth and survival of ovarian cancer cells, including those that were resistant to chemotherapy.

In addition to its potential use as a drug target, OR10J1 is also a potential biomarker for ovarian cancer. This is because its expression is often reduced in ovarian cancer cells, and levels of the protein can be used as a measure of the disease. For example, researchers have shown that levels of OR10J1 are often reduced in ovarian cancer cells, and that these levels can be used as a biomarker for the disease.

The potential use of OR10J1 as a drug target and biomarker for ovarian cancer makes it an important area of research. Further studies are needed to fully understand the potential of this protein and to develop effective treatments for ovarian cancer.

Protein Name: Olfactory Receptor Family 10 Subfamily J Member 1

Functions: Odorant receptor

The "OR10J1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR10J1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2 | OR11H1 | OR11H12 | OR11H13P | OR11H2 | OR11H5P | OR11H6 | OR11H7 | OR11J2P | OR11J5P | OR11K2P | OR11L1 | OR11M1P | OR12D2 | OR12D3 | OR13A1 | OR13C2 | OR13C3 | OR13C4 | OR13C5 | OR13C8 | OR13C9 | OR13D1 | OR13F1 | OR13G1 | OR13H1 | OR13J1 | OR13Z2P | OR14A16 | OR14A2 | OR14C36 | OR14I1 | OR14J1 | OR14L1P | OR1A1 | OR1A2 | OR1B1 | OR1C1 | OR1D2 | OR1D4 | OR1D5 | OR1E1 | OR1E2 | OR1E3 | OR1F1 | OR1F2P | OR1G1 | OR1I1 | OR1J1 | OR1J2 | OR1J4 | OR1K1 | OR1L1 | OR1L3 | OR1L4 | OR1L6 | OR1L8 | OR1M1 | OR1N1 | OR1N2 | OR1P1 | OR1Q1 | OR1S1 | OR1S2 | OR2A1 | OR2A1-AS1 | OR2A12 | OR2A14 | OR2A2 | OR2A20P | OR2A25 | OR2A4 | OR2A42 | OR2A7 | OR2A9P | OR2AE1 | OR2AG1 | OR2AG2 | OR2AJ1 | OR2AK2 | OR2AL1P | OR2AM1P | OR2AP1 | OR2AT4 | OR2B11